Trials / Not Yet Recruiting
Not Yet RecruitingNCT07286266
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study specifically aims to evaluate how well GSK5733584 works in treating ovarian cancer compared to standard treatments. The study also assesses whether GSK5733584 is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK5733584 | GSK5733584 will be administered |
| DRUG | Paclitaxel | Paclitaxel will be administered |
| DRUG | Pegylated liposomal doxorubicin (PLD) | PLD will be administered |
| DRUG | Topotecan | Topotecan will be administered |
| DRUG | Gemcitabine | Gemcitabine will be administered |
Timeline
- Start date
- 2026-06-24
- Primary completion
- 2030-07-22
- Completion
- 2030-07-22
- First posted
- 2025-12-16
- Last updated
- 2026-03-19
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07286266. Inclusion in this directory is not an endorsement.